322 related articles for article (PubMed ID: 11801472)
1. Cladribine (2-chlorodeoxyadenosine) therapy in hairy cell leukemia variant. A report of three cases.
Palomera L; Domingo JM; Sola C; Azaceta G; Calvo MT; Gutierrez M
Haematologica; 2002 Jan; 87(1):107-8. PubMed ID: 11801472
[No Abstract] [Full Text] [Related]
2. Dyserythropoietic changes and sideroblastic anemia in patients with hairy cell leukemia before and after therapy with 2-chlorodeoxyadenosine.
Zák P; Chrobák L; Podzimek K; Plísková L; Dedic K
Neoplasma; 1998; 45(4):261-5. PubMed ID: 9890671
[TBL] [Abstract][Full Text] [Related]
3. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine).
Füreder W; Weltermann A; Chott A; Gisslinger H; Valent P; Jäger U; Geissler K; Lechner K
Wien Klin Wochenschr; 1999 Dec; 111(24):1027-30. PubMed ID: 10677889
[TBL] [Abstract][Full Text] [Related]
4. Treatment of patients with hairy cell leukemia with 2-chloro-2'-deoxyadenosine (2-CdA).
Robak T; Krykowski E; Błasińska-Morawiec M; Urbańska-Ryś H
Arch Immunol Ther Exp (Warsz); 1994; 42(1):25-9. PubMed ID: 7503629
[TBL] [Abstract][Full Text] [Related]
5. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications.
Lauria F; Bocchia M; Marotta G; Raspadori D; Zinzani PL; Rondelli D
Haematologica; 1999 Jan; 84(1):22-5. PubMed ID: 10091389
[TBL] [Abstract][Full Text] [Related]
6. Alemtuzumab (Campath 1H) in hairy cell leukaemia relapsing after rituximab treatment.
Fietz T; Rieger K; Schmittel A; Thiel E; Knauf W
Hematol J; 2004; 5(5):451-2. PubMed ID: 15448675
[No Abstract] [Full Text] [Related]
7. Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment.
Bastie JN; Cazals-Hatem D; Daniel MT; D'Agay MF; Rabian C; Glaisner S; Noel-Walter MP; Dabout D; Flandrin G; Dombret H; Poisson D; Degos L; Castaigne S
Leuk Lymphoma; 1999 Nov; 35(5-6):555-65. PubMed ID: 10609793
[TBL] [Abstract][Full Text] [Related]
8. Retrospective analysis of 34 cases of hairy cell leukemia treated with interferon-alpha and/or 2-chlorodeoxyadenosine.
Zaja F; Fanin R; Silvestri F; Russo D; Infanti L; Baccarani M
Haematologica; 1997; 82(4):468-70. PubMed ID: 9299866
[TBL] [Abstract][Full Text] [Related]
9. [Successful ambulatory treatment of patients with hairy-cell leukemia using one cycle of the purine analog cladribine. 'Hemato-oncologic volwassen Nederland' (HOVON) Study Group].
Raemaekers JM; van 't Veer MB; Bogman MJ
Ned Tijdschr Geneeskd; 1996 Aug; 140(31):1600-4. PubMed ID: 8768814
[TBL] [Abstract][Full Text] [Related]
10. Rapid and complete hematological response of refractory hairy cell leukemia to the BRAF inhibitor dabrafenib.
Vergote V; Dierickx D; Janssens A; Verhoef G; Tousseyn T; Vandenberghe P; Wolter P; Delforge M
Ann Hematol; 2014 Dec; 93(12):2087-9. PubMed ID: 24863690
[No Abstract] [Full Text] [Related]
11. [Hairy cell leukemia and its treatment with 2-chlorodeoxyadenosine (2-CdA)].
Pawelski S
Acta Haematol Pol; 1995; 26(2):139-43. PubMed ID: 7653218
[TBL] [Abstract][Full Text] [Related]
12. Hairy cell leukaemia, its therapy and prognosis (historical review with own experiences).
Chrobák L; Podzimek K; Zak P; Plísková L; Voglová J
Acta Haematol Pol; 1995; 26(2 Suppl 1):56-62. PubMed ID: 7653236
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study.
Johnston JB; Eisenhauer E; Wainman N; Corbett WE; Zaentz SD; Daeninck PJ
Semin Oncol; 2000 Apr; 27(2 Suppl 5):32-6. PubMed ID: 10877049
[TBL] [Abstract][Full Text] [Related]
14. The disease with hope: hairy cell leukemia.
Becker SE
Clin J Oncol Nurs; 2007 Oct; 11(5):731-5. PubMed ID: 17962181
[TBL] [Abstract][Full Text] [Related]
15. 2-chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia.
Robak T; Błasińska-Morawiec M; Krykowski E; Hansz J; Komarnicki M; Kazimierczak M; Konopka L; Maj S; Hellmann A; Zaucha JM; Urasiński L; Zdziarska B; Kotlarek-Haus S; Usnarska-Zubkiewicz L; Kuratowska Z; Dwilewicz-Trojaczek J; Hołowiecki J; Krawczyk-Kulis M; Grieb P
Leuk Lymphoma; 1996 Jun; 22(1-2):107-11. PubMed ID: 8724536
[TBL] [Abstract][Full Text] [Related]
16. Multiply relapsing hairy cell leukemia responsive to repeated courses of rituximab: a case report.
Buckstein R; Patel H; Chesney A; Reis M; Imrie K
Hematology; 2006 Aug; 11(4):267-70. PubMed ID: 17178666
[TBL] [Abstract][Full Text] [Related]
17. Transient eosinophilia in a patient with hairy-cell leukaemia treated with 2-chlorodeoxyadenosine.
Robak T; Błasińska-Morawiec M; Krykowski E
Acta Haematol Pol; 1992; 23(4):285-90. PubMed ID: 1363455
[TBL] [Abstract][Full Text] [Related]
18. Treatment of hairy-cell leukemia: current views.
Tallman MS; Peterson LC; Hakimian D; Gillis S; Polliack A
Semin Hematol; 1999 Apr; 36(2):155-63. PubMed ID: 10319384
[TBL] [Abstract][Full Text] [Related]
19. [Bone marrow changes in patients with hairy cell leukemia after 2-chlorodeoxyadenosine treatment].
Urasiński I; Zdziarska B; Krygier-Stojałowska A
Acta Haematol Pol; 1996; 27(1):49-55. PubMed ID: 8629443
[TBL] [Abstract][Full Text] [Related]
20. Rituximab: a useful drug for a repeatedly relapsed hairy cell leukemia patient.
Pollio F; Pocali B; Palmieri S; Morabito P; Scalia G; Del Vecchio L; Ferrara F
Ann Hematol; 2002 Dec; 81(12):736-8. PubMed ID: 12483372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
